Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective non-randomized efficacy trial of olaparib maintenance therapy after
frontline treatment with platinum-based therapy in advanced ovarian cancer patients with
BRCAwt, homologous recombination deficient (HRD) disease.